Highlights from the ENETS Annual Conference 2025 #1

nav.hidden, nav ul [x-cloak], nav ul li ul { display: block !important; } This website requires Javascript for some parts to function properly. Your experience may vary.

This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential Essential cookies enable basic functions and are necessary for the website to function properly. Marketing Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

Log out

Change Cookie Settings

Forgot Password? Click here

Cookie consent is required to register and log in

I am a Healthcare professional outside US

Subscribe me to the regular newsletter

Notice: The content of this website is not intended for U.S. residents.

This website has implemented reCAPTCHA v3 and your use of reCAPTCHA v3 is subject to the Google Privacy Policy and Terms of Use.

Log out

Change Cookie Settings

Forgot Password? Click here

Cookie consent is required to register and log in

I am a Healthcare professional outside US

Subscribe me to the regular newsletter

Notice: The content of this website is not intended for U.S. residents.

This website has implemented reCAPTCHA v3 and your use of reCAPTCHA v3 is subject to the Google Privacy Policy and Terms of Use.

Highlights from the ENETS Annual Conference 2025 #1

In part one of a two-part video series, nuclear medicine physician Chiara Maria Grana and medical oncologist Jaume Capdevila discussed the most exciting insights presented at the Annual Conference of the European Neuroendocrine Tumor Society e.V. (ENETS), which took place from March 5-7, 2025 at the ICE Kraków Congress Centre in Poland.

Back

With over 1,000 registered participants from various disciplines involved in managing patients with neuroendocrine tumors, the congress showcased potentially practice-changing clinical data in NET. This included the late-breaking abstracts featuring phase III results from the COMPETE and STARTER-NET trial and an update on the OCLURANDOM trial.

Related Assets

Expert interviews

Mar 2025

Highlights from the ENETS Annual Conference 2025 #2

In part two of this two-part video series, nuclear medicine physician Chiara Maria Grana and medical oncologist Jaume Capdevila share their key takeaways from ENETS 2025 directly from the ICE Kraków Congress Centre.

enets